FDA commish nominee's financial disclosures reveal a vast web of industry ties. Will they matter?
President Biden’s nominee to run the FDA was hit with some tepid criticism back in 2016 for being too cozy with the biopharma industry because some of the trials he ran had industry sponsors and some of the funding he took was from industry.
Nevertheless, Rob Califf sailed through his confirmation then, and his successor Scott Gottlieb showed that even closer ties to industry shouldn’t stop an effective leader from being FDA commissioner.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 129,700+ biopharma pros reading Endpoints daily — and it's free.